Diarrhoea during checkpoint blockade, not always colitis

Immune checkpoint inhibitors have radically changed the perspectives for many cancer patients. Blockade with antibodies against the checkpoints cytotoxic T-lymphocyte antigen 4, such as ipilimumab, and programmed cell death protein 1, such as pembrolizumab and nivolumab, augment the immunologic reaction against tumour cells. Immune checkpoint inhibitors can cause immune-related adverse events (irAEs) that may appear subclinical, can occur in multiple organs simultaneously and can be serious in nature.

from # All Medicine by Alexandros G. Sfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/2xZHEbu
via IFTTT